Tianjin Saixiang's "nanoknife" may be a form of precision surgery, but it is indicative of a broad trend that is reshaping China's economic relationship with the rest of the world.
Made by a little-known Chinese company, it is designed to target prostate cancer without invasive surgery. Tianjin Saixiang was given the official imprimatur of "little giant" in 2020, meaning it qualifies for preferential treatment in return for helping China to climb the technology ladder.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
